The Global Diabetes Drugs Market is expected to reach US$ 78,261.7 mn by 2026 owing to rising prevalence of diabetes the world over. Key insights into this growing market have been shared by Fortune Business Insights in its report, titled “Diabetes Drugs Market Size, Share and Global Trend By Drug Class (Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors), Diabetes Type (Type 1, Type 2), Route of Administration (Oral, Subcutaneous, Intravenous), Distribution Channel (Online pharmacies, Hospital Pharmacies, Retail Pharmacies) & Geography Forecast till 2026”.
Get Sample PDF Brochure @
The report comprehensively analyses the major factors that will influence the growth of the market. Diabetes is a chronic disease in which a person’s blood sugar or blood glucose gets too high. This glucose gets absorbed in the body through a hormone called insulin which is made in the pancreas. Insulin helps glucose enter the body’s cells, which, in turn, give the body energy to function.
“Some of the Main Key Players Covered in the Report”
- Johnson & Johnson
- Bayer Pharmaceuticals
- Eli Lilly and Company
- Takeda Pharmaceutical Company Limited
- Boehringer Ingelheim
Browse Complete Report Details @
“Undiagnosed Sections May Hinder Market Growth”
The Centre for Disease Control and Prevention revealed that around 7.2 mn people in the US remained undiagnosed in 2017. The global diabetes drugs market may see restrained growth as a result, since a large number of people remain untapped.
However, as lifestyles get more sedentary and diagnostic methods get more advanced, the market is sure to gain momentum between 2018 and 2026 and register a CAGR of 6.1%.
By Drug Class
- DPP-4 Inhibitors
- GLP-1 Receptor Agonists
- SGLT2 Inhibitors
By Diabetes Type
- Type 1
- Type 2
By Route of Administration
By Distribution Channel
- Online pharmacies
- Hospital Pharmacies
- Retail Pharmacies
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Order Full Report: https://www.fortunebusinessinsights.com/checkout-page/100570
“Rising Demand for Insulin Treatments to Surge the Market”
Insulin provides the one of the most efficient treatment methods for diabetes. As a result, there is a growing demand for low-cost insulin treatments, especially to combat Type 2 diabetes. The rapidly rising insulin segment is, therefore, expected to boost the global diabetes drugs market during the forecast period. This has also encouraged private and public investments in research and development, which, in turn, will accelerate market growth. For example, recently, a rapid-acting, low-cost insulin called Lispro was launched in its generic form by Eli Lilly and Company in the US.
“Market Competition Set to Intensify”
Key players are increasing their investments in research and development activities and launching new products to maintain their competitive edge. For example, in July 2019, the National Institute for Health and Care Excellence cleared Forxiga for treating Type 1 diabetes in England and Wales. The drug has been developed jointly by Bristol-Myers Squibb and AstraZeneca. The global diabetes drug market is expected to grow as a result.
More Trending Topics from Fortune Business Insights: